David J. Wambeke
David J. Wambeke's purchase track record
How the stock did after each of David J. Wambeke's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2026 | NMTC | $67K | pending | pending | — |
| 3/1/2026 | NMTC | $670K | -7.0% | -57.5% | +11.7% |
| 11/16/2023 | DMAC | $49K | +26.1% | +33.2% | +17.5% |
| 6/23/2023 | DMAC | $150K | -34.1% | -32.9% | +9.3% |
| 4/10/2023 | DMAC | $750K | +135.7% | +42.7% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
Transaction History
| NMTC | ▲ Buy | Open Market | 33,333 | $67K | 8/27/2026 | View on chart |
| NMTC | ▲ Buy | Open Market | 1,000,000 | $670K | 3/1/2026 | View on chart |
| DMAC | ▲ Buy | Open Market | 20,000 | $49K | 11/16/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 38,364 | $150K | 6/23/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 468,750 | $750K | 4/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NeuroOne Reports Strong Q4 Sales, New $4.5M Order
NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.
NeuroOne Reports Strong Q4 Sales, New $4.5M Order. NeuroOne Medical Technologies said its Q4 sales were about $3.8 million, up 38% from last year. The company also added a $4.5 million purchase order in September and expects FY26 sales of roughly $10.5 million, a 15.6% increase year‑over‑year. These results come as the share price sits near its 12‑touch support level of $1.63 and an RSI of 45.8.